Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia vi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Virol
Prif Awduron: Kibler, Karen V., Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L., Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C., Tomaras, Georgia D., Roederer, Mario, Foulds, Kathryn E., Forthal, Donald N., Seaman, Michael S., Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D., Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L., Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, Jacobs, Bertram L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2019
Pynciau:
Vaccines and Antiviral Agents
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6340019/
https://ncbi.nlm.nih.gov/pubmed/30429340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01513-18
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg